Squarepoint Ops LLC Outlook Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.02 - $1.89 $256,461 - $475,208	251,433 Added 385.99%	316,573 $550,000
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $65,140 - $87,939	65,140 New	65,140 $71,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $32,738 - $40,442	32,097 New	32,097 $39,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $29,068 - $64,205	-31,943 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $38,970 - $64,844	31,943 New	31,943 $57,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.23 $14,351 - $25,199	-11,300 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.12 - $2.76 $212 - $276	100 Added 0.89%	11,300 $25,000
Q2 2021 Aug 16, 2021	SELL	$1.78 - $2.76 $11,901 - $18,453	-6,686 Reduced 37.38%	11,200 $28,000
Q1 2021 May 17, 2021	BUY	$0.94 - $3.31 $16,812 - $59,202	17,886 New	17,886 $40,000
Q3 2020 Nov 16, 2020	SELL	$0.61 - $1.6 $9,878 - $25,910	-16,194 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.56 - $1.41 $9,068 - $22,833	16,194 New	16,194 $21,000
Q3 2019 Nov 14, 2019	SELL	$1.32 - $2.63 $36,550 - $72,824	-27,690 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$0.91 - $7.68 $25,197 - $212,659	27,690 New	27,690 $58,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.18B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.